Clinical trials: Conversion Disorder, open to volunteers
Biliary Tract Cancer
HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer
This is a single-arm, exploratory, phase II trial to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy combined with adebrelimab and lenvatinib for borderline resectable, locally advanced biliary tract…
- Trial name
- NCT06389500
- Testing
- Adebrelimab, Lenvatinib, Hepatic Arterial Infusion Chemotherapy
- Volunteers
- 30 people
- Sponsor
- Harbin Medical University
Gastric Cancer (GC), AFP Gastric or Gastroesophageal Junction Adenocarcinoma
Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma
Alpha-fetoprotein-producing gastric cancer (AFP-positive gastric cancer, AFP-GC), a rare and highly aggressive subtype of gastric cancer, accounts for 1.3% to 15% of all gastric cancer cases.
- Trial name
- NCT07515625
- Testing
- Sintilimab, Bevacizumab, Oxaliplatin
- Volunteers
- 46 people
- Sponsor
- Fudan University
Dissociative Identity Disorder (DID)
EXPLOration of Processes Involved in Dissociative Identity Disorder (DID)
Dissociative Identity Disorder (DID) is a psychological condition in which a person may feel as though they have multiple distinct personalities or identities.
- Trial name
- EXPLO-DID (NCT07663890)
- Testing
- Questionnaire and Physical Exam, Interview
- Where
- 4 sites in France
- Volunteers
- 60 people
- Sponsor
- Lille University
Multiple Sclerosis, Functional Neurological Disorders
Bridging Gaps in the Multidimensional Assessment and Management of Overlapping Symptoms in Multiple Sclerosis and Functional Motor Disorders: Prevalence and Rehabilitation Effectiveness
Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system that may cause a broad range of motor and non-motor symptoms.
- Trial name
- NCT07856485
- Testing
- Functional Motor Disorder-Specific Multidisciplinary Rehabilitation, Conventional Multiple Sclerosis Rehabilitation
- Where
- 2 sites in Italy
- Volunteers
- 192 people
- Sponsor
- IRCCS San Raffaele
MCI, MCI Conversion to Dementia
Neurocognitive Assessment Platform 4 Alzheimer
The aging population in Europe is leading to an increase in neurodegenerative diseases, such as Alzheimer's disease (AD), which is expected to affect 152 million people worldwide by 2050.
- Conditions
- MCI, MCI Conversion to Dementia, AMCI - Amnestic Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- NAP4A2020 (NCT07272811)
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Gastric Cancer
Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer
This study aims to evaluate the efficacy of disitamab vedotin in combination with sintilimab and SOX as conversion therapy in patients with initially unresectable locally advanced or metastatic gastric cancer exhibiting HER2 IHC…
- Trial name
- Remission (NCT07194005)
- Testing
- Disitamab vedotin(RC48), Sintilimab, S-1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma, Chemotherapy Effect
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
The goal of this clinical trial is to compare HAIC concurrently with sequentially combined with targeted and immunotherapies in terms of efficacy and safety in patients with potentially resectable intermediate and advanced HCC…
- Conditions
- Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity
- Trial name
- HAIC (NCT06041477)
- Testing
- Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU, Concurrent Lenvatinib, Concurrent PD-1 antibody
- Where
- China
- Volunteers
- 540 people
- Sponsor
- Sun Yat-sen University
Breast Cancer, Triple Negative Breast Cancer
Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)
This is a single centre Window-of-Opportunity trial investigating the efficacy and feasibility of short term imatinib in patients with newly diagnosed triple negative breast cancer (TNBC) planned for surgery, with tumours ≥ 15…
- Trial name
- I-CONIC (NCT05722795)
- Testing
- Imatinib 400 MG Oral Tablet
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Vastra Gotaland Region
Gastric Adenocarcinoma, Stomach Neoplasms
Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
This is a randomized, controlled, multicenter phase II clinical trial evaluating the efficacy and safety of conversion therapy combined with radical gastrectomy and adjuvant radiotherapy targeting para-aortic (station 16) lymph…
- Trial name
- NCT07007182
- Testing
- SOX regimen, CAPEOX regimen, PD-1 inhibitor
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Jinbo Yue
HCC - Hepatocellular Carcinoma
A Prospective Observational Cohort Study on Dynamic CD8+ T-cell Profiling and Multi-omics Biomarkers for Predicting Conversion Therapy Response in Unresectable Hepatocellular Carcinoma
This study aims to identify early predictors for successful liver cancer treatment conversion. We will track changes in immune cells (CD8+ T-cells) in the blood during chemotherapy infusion (HAIC/TACE) combined with…
- Trial name
- NCT07117279
- Volunteers
- 120 people
- Sponsor
- Tongji Hospital
Unresectable Hepatocellular Carcinom
Conversion Therapy Using TACE/HAIC With Anti-Angiogenic and Immunotherapy for Initially Unresectable Hepatocellular Carcinoma Achieving Complete Response or Resectability, Followed by Surgery or Continued Systemic Treatment: A Prospective Cohort Study
This is a prospective cohort study designed to evaluate the effectiveness and safety of two post-conversion treatment strategies for patients with initially unresectable hepatocellular carcinoma (uHCC).
- Trial name
- THAI-CONVERT (NCT07206511)
- Volunteers
- 278 people
- Sponsor
- Shanghai Zhongshan Hospital
Well-Being, Psychological, Mood Disturbance
Neurofeedback and Well-Being Among People With Co-Occurring Obsessive Compulsive Disorder and Post-traumatic Stress Symptoms
The proposed study will collect novel data evaluating the feasibility of a neurofeedback training program delivered to prospective clients with a history of clinically concerning trauma-related mental health symptoms who are on a…
- Conditions
- Well-Being, Psychological, Mood Disturbance, Emotional Regulation, Dissociation
- Trial name
- NCT07217925
- Testing
- Neuroptimal (Zengar, Inc.) Neurofeedback
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wayne State University
Dissociative Disorder
Evaluation of the Efficacy of Dissociation-Focused Cognitive Behavior Therapy
Dissociative symptoms and disorders are particularly prevalent in the general population and among people suffering from psychiatric disorders. To date, no treatment has proven effective for this type of problem.
- Trial name
- TCC-DISSO (NCT06917209)
- Testing
- CBT-CD psychotherapy
- Where
- 8 sites in France
- Volunteers
- 140 people
- Sponsor
- University Hospital, Tours
Spinal Cord Injury, Chronic Spinal Cord Injury
First-in-Human Clinical Trial of STUP-001, an In Vivo Direct Cell Conversion Gene Therapy for AIS-A/B Chronic Spinal Cord Injury
This study aim to investigate the safety and exploratory efficacy of STUP-001 which is AAV-based spinal cord injury investigational product.
- Trial name
- STUP-001 (NCT06922890)
- Testing
- STUP-001
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Yonsei University
Pancreatic Cancer
AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.
The goal of this interventional study is to learn about the clinical efficacy of sequential therapy (albumin paclitaxel, gemcitabine combined with PD-L1 antibodies, followed by liposomal irinotecan, oxaliplatin and 5-FU/LV…
- Trial name
- ZSPAC-14 (NCT07208539)
- Testing
- Treatment: AG & anti-PD-L1 + FOLFIRINOX & anti-PD-L1
- Volunteers
- 77 people
- Sponsor
- Shanghai Zhongshan Hospital
Colon Cancer
Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）
The goal of this clinical trial is to evaluate the efficacy and safety of conversion therapy using radiotherapy combined with systemic treatment (chemotherapy + immune checkpoint inhibitors) for patients with pMMR/MSS T4M0 stage…
- Trial name
- NCT06949111
- Testing
- radiotherapy, CAPOX, Capecitabine
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Hebei Medical University Fourth Hospital
Functional Neurological Disorder, Motor FND
Impact of Theta Burst Repetitive Transcranial Magnetic Stimulation on the Patient's Self-reported Improvement in Their Motor Functional Neurological Disorder
Functional neurological disorder (FND) is a condition that causes significant suffering and disability. It is defined by the presence of neurological symptoms that interfere with an individual's functioning and are not consistent…
- Trial name
- Thêta-mTNF (NCT07527403)
- Testing
- theta-burst rTMS (repetitive transcranial magnetic stimulation)
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Hospital Center Guillaume Régnier
Non Small Cell Lung Cancer (Stage III)
The Efficacy and Safety of Sintilimab Plus Chemotherapy in Surgical Conversion for Patients With Unresectable Stage IIIB-IIIC NSCLC: A Prospective, Single-Arm, Phase II Study
This study aimed to evaluate the conversion rate to curative-intent treatment in patients with unresectable stage IIIB-IIIC non-small cell lung cancer (NSCLC) following induction therapy with PD-1 blockade combined with…
- Trial name
- NCT06962189
- Testing
- chemoimmunothrapy
- Volunteers
- 39 people
- Sponsor
- Zhejiang University
Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC)
FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
This study is a prospective, multicenter Phase II trial evaluating a personalized treatment strategy for patients with unresectable hepatocellular carcinoma (HCC).
- Conditions
- Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC), Liver Cancer Adult
- Trial name
- FAD-HCC-001 (NCT07314372)
- Testing
- Camrelizumab Plus Apatinib, TACE Plus Camrelizumab and Apatinib
- Where
- China
- Volunteers
- 86 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Metastatic Colorectal Cancer
Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.
Most patients with mCRC are treated with palliative chemotherapy and only a small number of patients with limited metastatic disease achieve long-term remission following metastasectomy.
- Trial name
- CONVERSION (NCT03401294)
- Testing
- FOLFOXIRI and Bevacizumab
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- University of Saskatchewan